dhr stock price today

There are currently 3 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should «moderate buy» DHR shares. Strength was broad-based across both equipment and consumables, particularly in our industrial end markets. In its Life Science segment, the company reported 2.5% growth, boosted by 5.0% core revenue growth.

  • Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.
  • Danaher’s gross profit margin for the first quarter was 61%, while the operating margin of 25% was down 330 basis points.
  • LSB (LXU), another stock in the same industry, has yet to report results for the quarter ended March 2023.
  • A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return.
  • Click the link below and we’ll send you MarketBeat’s guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Our well-rounded performance is a testament to the durability and balanced positioning of our portfolio and our team’s commitment to leading and executing with the Danaher Business System. The company is seeing high growth in areas that are expected to be the backbone of its long-term growth. However, the impact of COVID is large, and I cannot blame investors for taking some money off the table as these tailwinds unwind – especially as I expect this unfavorable microenvironment to last. Funding levels and sales funnels remained healthy across most major geographies and end markets. The demand for our advanced solutions remains strong, notably for recent innovations such as the SCIEX ZenoTOF7600 and Leica Microsystems, Mika. Core revenue growth was down 4% with forex headwinds of 300 basis points.

While the valuation is fair, we’re not at prices that I would call attractive. I think DHR can go there if the market continues to weaken. That said, the company’s valuation has erased the entire surge caused by the pandemic. The implied price/free cash flow ratio is back to 2019 levels. As a result, Cepheid’s respiratory testing revenue of approximately $550 million in the quarter exceeded our expectation of $450 million. This was driven both by higher volumes and the preference for our 4-in-1 test for COVID-19, Flu A and B and RSV.

Stock Money Flow

This represents a $1.08 annualized dividend and a yield of 0.45%. The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. There’s life after COVID-19 for Danaher, and the stock has a long pathway https://g-markets.net/helpful-articles/the-5-different-types-of-doji-candlestick-patterns/ of growth ahead of it. On a risk/reward basis, they aren’t a great value right now, but these are excellent stocks to watch for a better entry point on. This is provided by Benzinga, and is indicative of the reason that the relevant security is potentially moving in any direction.

It also helps that more than half of this segment consists of water purification and related, which allows an industrial-focused segment to escape general economic weakness. Danaher’s gross profit margin for the first quarter was 61%, while the operating margin of 25% was down 330 basis points. The company generated $1.7 billion of free cash flow in the first quarter, which translates to a decline of 3.0%. In 1Q23, Danaher reported $7.2 billion in revenue, which is 6.4% below the prior-year quarter result and $140 million higher than expected. Based on that context, I’m writing this article with somewhat mixed feelings.

Currently, the analyst consensus on Danaher is a Strong Buy with an average price target of $277.76, representing a 18.46% upside. In a report released on July 6, Evercore ISI also maintained a Buy rating on the stock with a $260.00 price target. The good news is that I’m finally getting another opportunity to add DHR shares. DHR has become my second-smallest position, as I haven’t added a lot to the position in recent months. Also, its performance was lackluster, as investors aren’t keen on holding growth stocks in a high-rate environment. The featured stocks all trade at substantial discounts to analyst price targets.

Billionaire Ken Fisher Says Today’s «Doom and Gloom» Is a Bullish Sign. Here Are the Stocks He’s Betting On.

DHR earnings call for the period ending December 31, 2020. DHR earnings call for the period ending March 31, 2021. DHR earnings call for the period ending June 30, 2021.

dhr stock price today

This means that over the past quarter there has been an increase of insiders selling their shares of DHR in relation to earlier this year. Last month, Daniel Raskas, the SVP – Corporate Development of DHR sold 19,847.00 shares for a total of $4,535,039.50. The life sciences and diagnostics company’s guidance is getting complicated. Its revenue broke down by 10% basis points of this came from core weakness. What’s interesting is that this segment was significantly impacted by COVID.

Danaher Corp

This helps the valuation, as it would imply that the company trades at just 22x 2023E free cash flow. Last but not least, one of my favorite segments, Environmental & Applied Solutions, performed very well. This segment saw 5.0% revenue growth, as forex headwinds of 200 basis points offset 6.5% higher core growth. Margins improved by 420 basis points, most of which came from higher core margins. One major issue was related to the challenging macroeconomic environment, as the company witnessed softer demand globally at many of its emerging biotech customers. Pressures on liquidity and funding accelerated their efforts to conserve capital leading to project delays and cancellations.

dhr stock price today

Feel free to reach out to me via DMs or find me on Twitter (@Growth_Value_) for more insights. I anticipate that after 2023, Danaher’s stock price will rise again and outperform the market. In the meantime, I am eager to accumulate shares during any period of weakness. Furthermore, Radiometer experienced a significant increase in core growth driven by robust demand for blood gas testing in China. Similarly, Biosystems also observed mid-single-digit core growth, mainly led by advanced staining and digital pathology.

Earnings Transcripts

Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. The good news is that free cash flow is expected to continue growing. This year, the company is estimated to generate $7.8 billion in free cash flow, followed by consistent high-single-digit growth in the next few years.

In other words, the biotechnology segment is seeing some unwinding COVID-related benefits that are amplified by a very challenging funding (high rates) environment. We’d like to share more about how we work and what drives our day-to-day business. Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

  • The total value of a security’s shares, calculated by multiplying the total number of shares by the current price.
  • The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
  • Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity.
  • The total number of shares available for this security.

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank. Danaher shares have lost about 4.2% since the beginning of the year versus the S&P 500’s gain of 7.8%. After this year, when COVID headwinds fade, I expect the stock to restart a meaningful uptrend, hopefully, supported by higher general economic growth expectations.

See which 3 stocks are most likely to make moves following their insider activities. McNamara covers the Healthcare sector, focusing on stocks such as Thermo Fisher, Bio-Rad Laboratories, and Danaher. According to TipRanks, McNamara has an average return of -8.6% and a 15.63% success rate on recommended stocks. One share of DHR stock can currently be purchased for approximately $238.88. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

dhr stock price today

The company operates through three segments, including Life Sciences, Diagnostics, and Environmental & Applied Solutions. However, I am taking advantage of the stock price decline and am excited to increase my investment in Danaher. The company’s core business remains strong thanks to the secular growth in various sectors, and even its industrial segment has done well, as it has avoided general economic weakness. 16 Wall Street equities research analysts have issued «buy,» «hold,» and «sell» ratings for Danaher in the last year.

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians’ offices, reference laboratories, and other critical care settings. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. The company was founded in 1969 and is headquartered in Washington, the District of Columbia.

It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. LSB’s revenues are expected to be $180.3 million, down 9.4% from the year-ago quarter. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Diversified Operations is currently in the bottom 40% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

The total number of shares available for this security. The Price to Earnings ratio is generally considered an indicator of the value of a security (whether it is over or undervalued). This is calculated by dividing the current price quote by the Earnings per Share.